These 10 Cities Have More Skyscrapers Than Anywhere Else in the World
A version of this article originally appeared in Condé Nast Traveller India.
What counts as a skyscraper?
As per this data, a skyscraper refers to a completed building that is at least 150 meters (about 492 feet) tall. This benchmark is widely accepted in urban development and architectural databases as the minimum height for a high-rise structure to be classified as a skyscraper.
Where is the data from?
The rankings are based on the latest figures (as of July 2025) from the Council on Tall Buildings and Urban Habitat (CTBUH). The CTBUH tracks the height, construction status, and structural details of buildings worldwide, including commercial, residential, and mixed-use towers.
Does this data change often?
Yes. In fast-growing cities, especially in Asia and the Middle East, new skyscrapers are completed regularly, shifting the rankings every few months. The data in this story reflects the most recent available snapshot from CTBUH at the time of publication.
1. Hong Kong: over 550 skyscrapers
A shortage of flat land has made vertical development inevitable in Hong Kong.
CHUNYIP WONG
No city in the world has embraced vertical living like Hong Kong. With over 550 completed buildings taller than about 490 feet, the skyline is a forest of high-rises squeezed between mountainous terrain and the sea. A shortage of flat land, coupled with rapid economic growth in the late 20th century, made vertical development inevitable. Many of Hong Kong's residential skyscrapers are tightly packed and uniform, while commercial landmarks like the International Commerce Centre and Bank of China Tower punctuate the skyline with dramatic architectural flair.
2. Shenzhen, China: over 380 skyscrapers
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
2 minutes ago
- Washington Post
Prestige Consumer Healthcare: Fiscal Q1 Earnings Snapshot
TARRYTOWN, N.Y. — TARRYTOWN, N.Y. — Prestige Consumer Healthcare Inc. (PBH) on Thursday reported fiscal first-quarter earnings of $47.5 million. The Tarrytown, New York-based company said it had profit of 95 cents per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.01 per share.
Yahoo
29 minutes ago
- Yahoo
Finance Meets Fashion: Dan Ives and Snow Milk Drop Streetwear Collab
Wall Street's 'Best Dressed Man' Launches Apparel Line Dan Ives x Snow Milk BROOKLYN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- In an unexpected fusion of finance and street fashion, acclaimed Wall Street analyst Dan Ives is partnering with Brooklyn-based designer Snow Milk to launch an exclusive, unisex capsule collection. The Snow Milk x Dan Ives Collection features fashion with graffiti-inspired graphics and various designs associated with Dan Ives' colorful and unique fashion style. 'This collaboration means a lot to me. It's with a designer I admire and wear regularly,' said Dan Ives. 'I wanted to have clothes that many people inside and outside the Wall Street world can wear and have fun with. I'm excited about this fashion line." The collection includes men's and women's staples— including a long-sleeve button-down shirt for women and a short-sleeve polo shirt for men stamped with custom artwork, including one with a sleeve portrait of Ives sporting his well-known sunglasses and a cap. Founded by musician and artist, Doobie Duke Sims, Snow Milk has fans ranging from Whoopi Goldberg to tennis legend, Novak Djokovic. This marks the brand's first collaboration with a figure from the world of finance. 'We are so excited at Snow Milk to partner with Dan Ives, who has become globally known for his stock picks and colorful fashion sense,' said Doobie Duke Sims. The Snow Milk x Dan Ives Collection will be available online at and as well as in pop-up stores in New York City and Los Angeles, among other locations. About Dan Ives Dan is a veteran tech analyst with more than two decades of experience covering software and the broader technology landscape on Wall Street. His insights are regularly featured in global publications, and he is a frequent guest on financial television networks. In 2024, the New York Post named him the 'Best Dressed Man on Wall Street' in a featured fashion profile. He holds a B.S. in Finance from Penn State University and an MBA from the University of Maryland. About Snow Milk Snow Milk is a Brooklyn-based clothing label known for its unique, new and upcycled ethically produced streetwear. The brand focuses on creating one-of-a-kind pieces by hand-printing designs onto new and upcycled clothing. Each piece is individually numbered starting from 1 in 2021 and now currently at #70,000 in 2025. Media contact: Christina Scolaro, Zito Partners cscolaro@ +1 (917) 733-9697 A photo accompanying this announcement is available at
Yahoo
29 minutes ago
- Yahoo
Analysis-Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters
By Lewis Krauskopf NEW YORK (Reuters) -Woes for U.S. healthcare stocks have worsened this year driven partly by Trump administration policies, although some investors are betting that the beaten-down shares are now becoming too much of a bargain to pass up. The S&P 500 healthcare sector -- which includes pharmaceutical companies, biotechs, health insurers and medical equipment makers -- has slumped 5% in 2025, lagging the over 7% gain for the overall index. Pressure to bring down U.S. prescription drug prices to overseas rates, tariffs targeted at pharmaceuticals and cuts to areas such as health research funding and Medicaid are among the Trump administration actions clouding the outlook for the shares this year, investors said. Regulatory obstacles are compounding issues, including expiring drug patents and setbacks for bellwethers including UnitedHealth Group. "You have got this constant overarching political and regulatory overhang that doesn't really seem to subside with any administration," said Jared Holz, healthcare sector strategist at Mizuho Securities. "When you have so much nebulousness around the sector, it turns people off rather than invites them to the party." In another sign of the group losing favor, healthcare exchange-traded-funds have seen 12 consecutive months of net outflows as of July for a total outflow of $11.5 billion in that time, more than for any other sector, according to State Street Investment Management. The performance picture is even dimmer over a longer period. While shares of massive technology companies pushed the benchmark S&P 500 up over 50% the past three years, the healthcare sector is little changed in that time. That gap has put the 60-stock sector at nearly its biggest discount to the broader market in 30 years, which some investors hope is an inflection point for the battered group. "The valuation is extremely cheap and the relative performance is at an extreme," said Walter Todd, chief investment officer at Greenwood Capital, whose healthcare holdings include diversified giant Johnson & Johnson and medical device maker Stryker. "So at this point, it seems like a pretty decent setup to get some outperformance." The price-to-earnings ratio for the healthcare sector, based on earnings estimates for the next year, has fallen to 16.2 times from nearly 20 a year ago, according to LSEG Datastream. Meanwhile, the S&P 500's rally to records has driven the index's P/E ratio to over 22 times -- giving the broader market a significant premium over the healthcare sector. 'BAD NEWS IS PRICED IN' Some high-profile healthcare names are at even cheaper valuations. For example, Merck is trading at a forward P/E of 8.7, against its long-term average of 14.5, while fellow drugmaker Bristol Myers Squibb trades at 7.4 against its average of 15.8, according to LSEG. Year-to-date, shares of both Merck and Bristol Myers are down roughly 20%. The group is drawing bets from some value investors such as Patrick Kaser, portfolio manager at Brandywine Global, whose portfolio is overweight the sector including owning shares of CVS Health and European drugmakers GSK and Sanofi. "Our perspective is a lot of this bad news is priced in and then some," Kaser said. "To bet against the sector from here, you're essentially continuing to bet on the valuation gap, which is already large, continuing to widen." The group's decline means the total market value of the S&P 500 healthcare sector is about $4.8 trillion, not much higher than the $4.3 trillion value of Nvidia, the semiconductor company that has symbolized the artificial intelligence boom. Indeed, some investors said a shift in capital away from Nvidia and other massive tech companies could spark healthcare shares. Such a move appeared to occur in the first quarter, investors said, when the healthcare sector rose 6% while declines in tech and megacap stocks dragged indexes lower. Fears of an economic downturn also could help healthcare shares, at least on a relative basis. The group is often viewed as a defensive area in rockier economic times. Economic fears flared following last Friday's weaker-than-expected employment report, while some strategists say the market could be due for a pullback after surging over 20% since its April lows. "During the first quarter, healthcare did great even as tech rolled over, as the fears of an economic slowdown got to more economically sensitive stocks," said Chris Grisanti, chief market strategist at MAI Capital Management, adding he expects healthcare "will perform better in a more difficult market." More clarity on regulatory issues, including tariffs, also could support healthcare, investors said. But some value investors are hesitant to dive into the group. Michael Mullaney, director of global markets research at Boston Partners, said he is wary some healthcare shares could be "value traps," preferring to overweight areas including industrials or financials. "There's been just so much of an overhang in the sector," Mullaney said. "There are better places to go with cleaner stories." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
